Early observations and pilot data that first suggested a new direction
Aggressive intravenous fluid resuscitation was long considered a cornerstone of early acute pancreatitis management, based on pathophysiological reasoning that pancreatic inflammation caused massive third-spacing and microcirculatory failure. International guidelines recommended rapid, large-volume crystalloid administration (250-500 mL/hour) in the first 12-24 hours. However, this practice was supported primarily by observational data and expert opinion, with concerns about fluid overload complications emerging from clinical experience.
Landmark RCTs and pivotal trials that established the evidence base
The WATERFALL trial directly challenged the aggressive hydration paradigm. This multicenter RCT at 18 centers randomized patients with acute pancreatitis to goal-directed aggressive (20 mL/kg bolus followed by 3 mL/kg/hour) versus moderate (1.5 mL/kg/hour, with bolus only if hypovolemic) resuscitation with lactated Ringer solution. The trial was stopped early after 249 patients when the aggressive group showed significantly more fluid overload (adjusted RR 2.85; 95% CI 1.36-5.94) without improvement in the primary outcome of moderately severe or severe pancreatitis.
Follow-up studies, subgroup analyses, and real-world validation
Post-WATERFALL, the field shifted toward goal-directed moderate resuscitation as the standard approach. Subsequent analyses emphasized that fluid therapy needed to be individualized based on clinical markers of perfusion and volume status rather than applied as a fixed-volume protocol. The choice of lactated Ringer over normal saline gained support from physiological rationale and observational data showing reduced SIRS with balanced crystalloids. The WATERLAND trial was initiated to directly compare these two fluid types.
Integration into clinical practice guidelines and recommendations
Post-WATERFALL, updated guidelines shifted from recommending aggressive hydration to endorsing goal-directed moderate fluid resuscitation. The ACG and AGA guidelines now recommend lactated Ringer as the preferred crystalloid, with moderate initial rates (1.5 mL/kg/hour) titrated to clinical response markers including urine output, heart rate, and hematocrit.
ACG
Goal-directed moderate fluid resuscitation with lactated Ringer's preferred; aggressive hydration not recommended
AGA
Goal-directed fluid therapy; lactated Ringer's conditionally recommended over normal saline
Now
Current standard of care and ongoing research directions
The WATERFALL trial fundamentally changed acute pancreatitis fluid management by demonstrating that aggressive resuscitation caused harm without benefit. Goal-directed moderate resuscitation with lactated Ringer is now standard. Remaining questions include the optimal crystalloid type (WATERLAND trial ongoing), ideal resuscitation targets, and whether individualized fluid protocols guided by point-of-care ultrasound or other hemodynamic monitoring can further improve outcomes.
What did the WATERFALL trial change about pancreatitis fluid management?+
The WATERFALL trial (249 patients, NEJM 2022) showed that aggressive fluid resuscitation (20 mL/kg bolus + 3 mL/kg/hr) caused nearly 3-fold more fluid overload (adjusted RR 2.85) compared to moderate resuscitation (1.5 mL/kg/hr) without reducing the incidence of moderately severe or severe pancreatitis. The trial was stopped early for safety, overturning the prior paradigm of aggressive early hydration.
What fluid type is recommended for acute pancreatitis?+
Lactated Ringer's solution is preferred over normal saline based on physiological rationale (reduced hyperchloremia, lower SIRS rates in observational studies) and guideline recommendations from the AGA and ACG. The WATERLAND trial is ongoing to provide direct RCT evidence comparing these two crystalloids.
